<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals</h2>
    <div class="badge">2025-09-15T11:30:00+00:00</div>
    <ul>
      <li>A consensus price target of $496.05 implies a gain of about 26% from its closing price on Sep.</li>
<li>Investment bankers up and down Wall Street were pleased with second-quarter sales that rose 12% year over year to reach $2.96 billion, but it&#x27;s the reason behind the outstanding sales performance that makes the stock a W</li>
<li>12, 2025.</li>
<li>Should you invest $1,000 in Vertex Pharmaceuticals right now?</li>
<li>Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) have risen more than 2,000% over the past 20 years.</li>
<li>This would be a steep valuation for most established drugmakers, but not one that&#x27;s growing sales by more than 10% annually.</li>
<li>The 10 stocks that made the cut could produce monster returns in the coming years.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals\n• A consensus price target of $496.05 implies a gain of about 26% from its closing price on Sep.\n• Investment bankers up and down Wall Street were pleased with second-quarter sales that rose 12% year over year to reach $2.96 billion, but it&#x27;s the reason behind the outstanding sales performance that makes the stock a W\n• 12, 2025.\n• Should you invest $1,000 in Vertex Pharmaceuticals right now?\n• Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) have risen more than 2,000% over the past 20 years.\n• This would be a steep valuation for most established drugmakers, but not one that&#x27;s growing sales by more than 10% annually.\n• The 10 stocks that made the cut could produce monster returns in the coming years." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/m/ec42abf6-9d2e-31f9-98b2-24ef2ec2de13/1-reason-wall-street-is.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>